Package Leaflet: Information for the User
TRIAXIS POLIO, injectable suspension in a pre-filled syringe
Vaccine against diphtheria, tetanus, pertussis (acellular component) and poliomyelitis (inactivated, reduced antigen content)
Read all of this leaflet carefully before you or your child are vaccinated because it contains important information for you.
Contents of the package leaflet
Triaxis Polio (Tdap-IPV) is a vaccine. Vaccines are used to protect against infectious diseases. Vaccines make the body produce its own protection against the bacteria and viruses that cause these infectious diseases.
This vaccine is used as a booster to protect against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis (polio) in children from 3 years of age, adolescents, and adults after completing the primary vaccination schedule.
The use of Triaxis Polio during pregnancy allows the protection to be transferred to the child in the womb against whooping cough during the first months of life.
Limitations of the protection provided
Triaxis Polio will only prevent these diseases if they are caused by the bacteria or viruses used to produce the vaccine. It is possible that you or your child may suffer from similar diseases that are caused by other bacteria or viruses.
Triaxis Polio does not contain any live bacteria or viruses and cannot cause any of the infectious diseases it protects against.
Remember that no vaccine can offer complete and long-lasting protection to all people who are vaccinated.
To ensure that Triaxis Polio is suitable for you or your child, it is important that you tell your doctor or nurse if any of the following apply to you or your child. If there is anything you do not understand, ask your doctor or nurse.
Do not use Triaxis Polio if you or your child
Warnings and precautions
Consult your doctor or nurse before vaccination if you or your child:
It is possible that the vaccine may not protect these individuals in the same way as it protects people with a healthy immune system. If possible, vaccination should be postponed until the end of such illness or treatment.
After any injection with a needle, or even before, fainting can occur. Therefore, inform your doctor or nurse if you or your child have fainted with any previous injection.
Other medicines or vaccines and Triaxis Polio
Tell your doctor or pharmacist if you or your child are using or have recently used any other medicines.
Since Triaxis Polio does not contain any live bacteria or viruses, it can be administered at the same time as other vaccines or immunoglobulins, although in a different injection site. There are studies that have shown that Triaxis Polio can be used at the same time as some of the following vaccines: inactivated influenza vaccine, hepatitis B vaccine, and human papillomavirus vaccine, respectively. Injections of more than one vaccine at the same time will be given in different limbs.
If you or your child are receiving medical treatment that affects your blood or immune system (such as anticoagulants, steroids, or chemotherapy), consult the previous section "Warnings and precautions".
Pregnancy, breastfeeding, and fertility
Consult your doctor or nurse if you are pregnant, think you may be pregnant, or are planning to become pregnant or are breastfeeding. Your doctor or nurse will help you decide whether you should receive Triaxis Polio during pregnancy.
Driving and using machines
No studies have been performed on the effects on the ability to drive and use machines. The vaccine has a negligible influence on the ability to drive and use machines.
Triaxis Polio contains Ethanol
Triaxis Polio contains 1.01 milligrams of alcohol (ethanol) per 0.5 ml dose. The small amount of alcohol in this medicine will not produce noticeable effects.
When will you or your child receive the vaccine
Your doctor will decide whether Triaxis Polio should be administered to you or your child, based on:
Your doctor will decide what period to wait between vaccinations.
If you are pregnant, your doctor will help you decide whether you should receive Triaxis Polio during pregnancy.
Dosage and administration
Who will administer Triaxis Polio to you?
Triaxis Polio should be administered by trained healthcare professionals in the use of vaccines and in a clinic or outpatient setting with the necessary equipment to treat any severe allergic reaction to the vaccine.
Dosage
All age groups for which Triaxis Polio is indicated will receive one injection (0.5 ml).
In case you or your child experience an injury that requires preventive action against tetanus, your doctor may decide to give you Triaxis Polio with or without tetanus immunoglobulin.
Triaxis Polio can be used for booster vaccination. Your doctor will recommend repeating the vaccination.
Administration
The doctor or nurse will administer the vaccine into a muscle in the upper outer part of the arm (deltoid muscle).
The doctor or nurse will notadminister the vaccine into a blood vessel, buttocks, or under the skin. In case of blood coagulation disorders, they may decide to inject under the skin, although this may cause more local side effects, including a small lump under the skin.
If you have any doubts about the use of this medicine, consult your doctor or pharmacist or nurse.
Like all medicines, Triaxis Polio can cause side effects, although not everybody gets them.
Severe allergic reactions
If any of the following symptoms occur after leaving the place where you or your child received the injection, you must consult a doctor IMMEDIATELY.
When these signs or symptoms occur, they usually develop very quickly after the injection and while you or your child are still in the doctor's office. Severe allergic reactions are a very rare possibility (may affect up to 1 in 10,000 people) after receiving any vaccine.
Other side effects
The following side effects were observed during clinical studies conducted in specific age groups.
In children between 3 and 6 years of age
Very common (may occur in more than 1 in 10 people):
Common (may occur in up to 1 in 10 people):
In adolescents (11 years of age or older) and adults
Adolescents are slightly more likely than adults to experience side effects. Most side effects occur within the first 3 days after vaccination.
Very common (may occur in more than 1 in 10 people):
Common (may occur in up to 1 in 10 people):
The following additional adverse events have been reported in the recommended age groups during commercial use of Triaxis Polio. It is not possible to calculate the frequency of these adverse events with precision, as they are based on voluntary reports of notification in relation to the estimated number of people vaccinated.
Lymph node disorder, allergic reactions/severe allergic reactions, seizures (convulsions), fainting, paralysis of part or all of the body (Guillain-Barré syndrome), facial paralysis, spinal cord inflammation, arm nerve inflammation (brachial neuritis), temporary or altered sensation in the vaccinated limb, dizziness, pain in the vaccinated limb, extensive swelling of the limbs (often associated with redness and sometimes with blisters), feeling unwell, pale skin, lump (induration) at the injection site, abdominal pain.
Reporting of side effects
If you or your child experience any side effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Medicines and Healthcare Products Agency (AEMPS) website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use Triaxis Polio after the expiry date stated on the packaging and label after EXP. The expiry date is the last day of the month stated.
Store in a refrigerator (between 2°C and 8°C). Do not freeze. Discard the vaccine if it freezes.
Keep the syringe in the outer packaging to protect it from light.
Medicines should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medicine in the SIGRE collection point at the pharmacy. If you have any doubts, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Triaxis Polio
The active substances of each dose (0.5 ml) of vaccine are:
Diphtheria toxoid not less than 2 international units (2 Lf)Tetanus toxoid not less than 20 international units (5 Lf)Pertussis antigens: Pertussis toxoid 2.5 micrograms Filamentous hemagglutinin 5 micrograms Pertactin 3 micrograms Fimbriae types 2 and 3 5 micrograms
Inactivated Poliovirus (grown in Vero cells):
Type 1 (Mahoney) 29 units of antigen D1
Type 2 (MEF1) 7 units of antigen D1
Type 3 (Saukett) 26 units of antigen D1
Adsorbed on aluminum phosphate 1.5 mg (0.33 mg of Al3+)
1 These antigen quantities are strictly the same as those previously expressed as 40-8-32 units of antigen D, for virus types 1, 2, and 3, respectively, when measured by another suitable immunochemical method.
The aluminum phosphate in the vaccine is an adjuvant. Adjuvants are substances included in some vaccines to accelerate, enhance, or prolong the protective effects of the vaccine.
The other ingredients are: phenoxylethanol, ethanol, polysorbate 80, water for injections.
Appearance of the product and pack contents
Triaxis Polio is presented as an injectable suspension in a pre-filled syringe (0.5 ml):
Not all pack sizes may be marketed.
The normal appearance of the vaccine is a white and turbid suspension, which may sediment during storage. After correct shaking, the liquid has a uniform white appearance.
Marketing authorization holder and manufacturer
The marketing authorization holder is:
Sanofi Winthrop Industrie
82 avenue Raspail
94250 Gentilly
France
The manufacturer is:
Sanofi Winthrop Industrie
1541 avenue Marcel Mérieux
69280 Marcy l’Etoile
France
or
Sanofi Winthrop Industrie
Voie de l’Institut – Parc Industriel d’Incarville
B.P 101
27100 Val de Reuil
France
or
Sanofi-Aventis Zrt.
Campona Utca. 1 (Harbor Park)
H-1225 Budapest
Hungary
Local representative
sanofi-aventis, S.A.
C/ Rosselló i Porcel, 21
08016 Barcelona - Spain
Tel: +34 93 485 94 00
This medicine has been authorized in the EEA Member States under the following names:
Austria, Germany, Denmark, Finland, France, Greece, Ireland, Iceland, Norway, Portugal, Sweden, United Kingdom (Northern Ireland): | REPEVAX |
Belgium, Italy, Luxembourg, Netherlands, Spain: | TRIAXIS POLIO |
Bulgaria, Croatia, Slovakia, Slovenia, Hungary, Poland, Czech Republic, Romania: | ADACEL POLIO |
Date of last revision of this leaflet:February 2023
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/
This information is intended only for healthcare professionals:
Instructions for use
In the absence of compatibility studies, Triaxis Polio should not be mixed with other medicines.
Parenteral biological products should be inspected visually for particulate matter and/or discoloration before administration. If these conditions occur, the product should not be administered.
For products without a needle, the needle should be firmly attached to the end of the pre-filled syringe by a 90-degree turn.
Do not replace the needle cap.